Bufalin Suppresses Ovarian Cancer Cell Proliferation via the EGFR Pathway

0
0
0

Bufalin Suppresses Ovarian Cancer Cell Proliferation via the EGFR Pathway

Ovarian cancer is the seventh deadliest cancer for women globally, with a 5-year survival rate stuck at just 40%—a number that hasn’t improved meaningfully in a decade. Despite advances in surgery, chemotherapy, and targeted therapy, researchers are still searching for new ways to tackle this aggressive disease. One promising candidate? Bufalin, a compound extracted from Chansu (dried venom of the Chinese toad Bufo gargarizans), a traditional Chinese medicine (TCM) used for centuries to treat detoxification, swelling, and pain. While bufalin is known to fight other cancers—like gastric and pancreatic cancer—its exact mechanism in ovarian cancer remained unclear. A 2022 study published in the Chinese Medical Journal aimed to change that, uncovering how bufalin targets a key cancer-driving pathway to stop ovarian cancer cells from growing.

The Study: Who Did It and What They Wanted to Learn

The research team included Lei Dou, Dan Zou, Feiran Song, Yuxin Jin, Yin Li, and Yi Zhang from two leading Chinese institutions: the First Affiliated Hospital of China Medical University (Shenyang) and the Department of Integration of Chinese and Western Medicine at Peking University (Beijing). Their goal was simple: figure out how bufalin inhibits ovarian cancer cell proliferation—a critical step in tumor growth and spread.

How They Tested Bufalin’s Effects

The team focused on SK-OV-3, a widely used ovarian cancer cell line, and used five key experiments to measure bufalin’s impact:

  1. MTT Assay: This test tracks cell viability (how many cells stay alive after treatment). The researchers exposed SK-OV-3 cells to bufalin doses ranging from 0 to 400 nmol/L for 24 or 48 hours, then measured survival.
  2. EdU Assay: Short for 5-ethynyl-2’-deoxyuridine, this chemical tags new DNA—so the team could see if bufalin stopped cells from replicating their genetic material (a must for cell division).
  3. Colony Formation Assay: To check long-term growth, cells were treated with bufalin for 24 hours, then allowed to grow for 10 days. The team counted and measured colonies (clusters of cells) to see if bufalin prevented sustained growth.
  4. Molecular Docking: A computer simulation that predicts if two molecules (bufalin and the epidermal growth factor receptor, or EGFR) can bind together. EGFR is a protein overexpressed in many cancers that drives cell growth.
  5. Western Blotting: This lab technique measures protein levels. The team looked at:
    • EGFR itself (total protein),
    • “Active” EGFR (phosphorylated EGFR, or p-EGFR—phosphorylation is a chemical change that turns proteins on),
    • Two downstream proteins (AKT and ERK) that EGFR activates to promote cell growth.

The Results: Bufalin Stops Ovarian Cancer Cells in Their Tracks

The findings were clear—and promising:

  • Dose- and Time-Dependent Growth Inhibition: Bufalin worked better with higher doses and longer exposure. For example, the “half-maximal inhibitory concentration” (IC50)—the dose needed to kill 50% of cells—dropped from 212 nmol/L at 24 hours to just 74 nmol/L at 48 hours. This means longer treatment made bufalin far more effective.
  • Reduced DNA Replication: The EdU assay showed that higher bufalin doses drastically cut down on new DNA production. Without new DNA, cells can’t divide—a direct hit to proliferation.
  • Fewer, Smaller Colonies: The colony formation test confirmed bufalin’s long-term impact: more bufalin meant fewer, smaller clusters of cells. This proved bufalin doesn’t just kill cells temporarily—it stops them from growing back.
  • Bufalin Binds EGFR: Molecular docking revealed a strong interaction between bufalin and EGFR (a “docking score” of -3.515, meaning they bind tightly).
  • Blocked the EGFR/AKT/ERK Pathway: Western blotting showed bufalin reduced both total EGFR and its active (phosphorylated) form. It also turned off AKT and ERK—two proteins that EGFR uses to tell cells to grow.

Why This Matters: EGFR Is a Key Cancer Target

EGFR is a big deal in oncology. It’s a transmembrane protein that sits on cell surfaces and acts like a “growth switch”: when activated by molecules like epidermal growth factor (EGF), it triggers pathways (like AKT/ERK) that tell cells to divide, survive, and spread. In ovarian cancer, EGFR is often overexpressed—and higher levels correlate with worse survival.

Previous studies showed bufalin fights other cancers by targeting pathways like mTOR (in ovarian cancer) or mitochondrial ROS (in nasopharyngeal cancer). But this is the first time researchers have linked bufalin to the EGFR/AKT/ERK pathway in ovarian cancer—a critical missing piece in understanding how bufalin works.

The team also noted a promising lead: bufalin might reduce EGFR levels by blocking SOX2, a protein that “turns on” the EGFR gene. SOX2 is often overactive in cancers, so targeting it could be another way bufalin fights tumors (though more research is needed to confirm this).

What This Means for Ovarian Cancer Treatment

Ovarian cancer’s low survival rate is partly due to late diagnosis and resistance to existing treatments. Bufalin, a natural compound with a long history in TCM, offers a new angle: targeting EGFR and its downstream pathway to stop cell proliferation. For patients with EGFR-overexpressing ovarian cancer, this could mean a new treatment option—especially since some tumors become resistant to existing EGFR inhibitors.

The study’s authors emphasize that more research is needed (like animal studies and clinical trials) to confirm bufalin’s effects in humans. But their findings add to a growing body of evidence that combining traditional and modern medicine could unlock better cancer therapies.

This study was funded by the Special Project for Central Guidance of Local Science and Technology Development of Liaoning Province (No. 2019JH6/10400006). The original research was published in the Chinese Medical Journal (2022;135(4)).

doi.org/10.1097/CM9.0000000000001879

Was this helpful?

0 / 0